牛牛AI助理已提取核心訊息
60 Degrees Pharmaceuticals, trading under the symbol SXTP on The Nasdaq Capital Market, has filed a prospectus supplement on July 24, 2024, to increase the maximum aggregate gross sales price of shares offered under its Sales Agreement with WallachBeth Capital LLC to $1,890,705. This move, referred to as the ATM Offering Size Increase, amends previous registrations of common stock worth $1,253,603 and $1,774,640. As of the filing date, 60 Degrees Pharmaceuticals has sold 4,964,249 shares for a gross sales price of $0.2811 per share. The company's outstanding common stock held by non-affiliates is valued at approximately $5,672,117, based on a share price of $0.351 as of June 7, 2024. The company adheres to the SEC's General Instruction I.B.6 of Form S-3, which limits the sale of securities in a public primary offering to no more than one-third of the public float in a 12-month period, provided the public float is below $75 million. The prospectus supplement also highlights significant investment risks, as detailed in the Risk Factors sections of the accompanying documents and filings with the SEC.
60 Degrees Pharmaceuticals, trading under the symbol SXTP on The Nasdaq Capital Market, has filed a prospectus supplement on July 24, 2024, to increase the maximum aggregate gross sales price of shares offered under its Sales Agreement with WallachBeth Capital LLC to $1,890,705. This move, referred to as the ATM Offering Size Increase, amends previous registrations of common stock worth $1,253,603 and $1,774,640. As of the filing date, 60 Degrees Pharmaceuticals has sold 4,964,249 shares for a gross sales price of $0.2811 per share. The company's outstanding common stock held by non-affiliates is valued at approximately $5,672,117, based on a share price of $0.351 as of June 7, 2024. The company adheres to the SEC's General Instruction I.B.6 of Form S-3, which limits the sale of securities in a public primary offering to no more than one-third of the public float in a 12-month period, provided the public float is below $75 million. The prospectus supplement also highlights significant investment risks, as detailed in the Risk Factors sections of the accompanying documents and filings with the SEC.
60 Degrees Pharmaceuticals在納斯達克資本市場上交易的標的爲SXTP，於2024年7月24日提交了一份招股說明書補充，以增加在其與WallachBeth Capital LLC的銷售協議下提供的股票的最大總銷售價格至1,890,705美元。此舉被稱爲ATm Offering Size Increase，並修改了先前價值1,253,603美元和1,774,640美元普通股的註冊。截至申報日期，60 Degrees Pharmaceuticals已出售4,964,249股股票，股票的銷售價格爲每股0.2811美元。公司的未發行普通股由非關聯方持有，價值約爲5,672,117...展開全部
60 Degrees Pharmaceuticals在納斯達克資本市場上交易的標的爲SXTP，於2024年7月24日提交了一份招股說明書補充，以增加在其與WallachBeth Capital LLC的銷售協議下提供的股票的最大總銷售價格至1,890,705美元。此舉被稱爲ATm Offering Size Increase，並修改了先前價值1,253,603美元和1,774,640美元普通股的註冊。截至申報日期，60 Degrees Pharmaceuticals已出售4,964,249股股票，股票的銷售價格爲每股0.2811美元。公司的未發行普通股由非關聯方持有，價值約爲5,672,117美元，截至2024年6月7日，股票價格爲0.351美元。公司遵守SEC Form S-3的I.b.6常規指示，該指導方針規定在12個月內的公開首次發行中，不得超過公開浮動金額的三分之一，前提是公開浮動金額不超過7500萬美元。招股書補充還強調了重大投資風險，詳見附隨文件及向SEC提交的文件中的風險因素部分。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了